JPH0363229A - Medicine composition having antitumor action - Google Patents
Medicine composition having antitumor actionInfo
- Publication number
- JPH0363229A JPH0363229A JP1201537A JP20153789A JPH0363229A JP H0363229 A JPH0363229 A JP H0363229A JP 1201537 A JP1201537 A JP 1201537A JP 20153789 A JP20153789 A JP 20153789A JP H0363229 A JPH0363229 A JP H0363229A
- Authority
- JP
- Japan
- Prior art keywords
- tincture
- extract
- tinctures
- chinese herb
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title abstract description 10
- 239000003814 drug Substances 0.000 title abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 45
- 229940098465 tincture Drugs 0.000 claims abstract description 29
- 230000000694 effects Effects 0.000 claims abstract description 16
- 230000000767 anti-ulcer Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229940002508 ginger extract Drugs 0.000 claims 1
- 235000020708 ginger extract Nutrition 0.000 claims 1
- 235000008216 herbs Nutrition 0.000 claims 1
- 229940069445 licorice extract Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 11
- 208000025865 Ulcer Diseases 0.000 abstract description 7
- 231100000397 ulcer Toxicity 0.000 abstract description 7
- 241000365321 Sophoreae Species 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000202807 Glycyrrhiza Species 0.000 description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 5
- 208000008469 Peptic Ulcer Diseases 0.000 description 5
- 229940010454 licorice Drugs 0.000 description 5
- 230000002467 anti-pepsin effect Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- -1 etc.) Substances 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 208000011906 peptic ulcer disease Diseases 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000007721 medicinal effect Effects 0.000 description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は抗潰瘍作用、特に抗消化性潰瘍作用を有する新
規な漢方医薬組成物に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a novel Chinese herbal medicine composition having anti-ulcer activity, particularly anti-peptic ulcer activity.
漢方製剤は種々の組合わせによってそれぞれに特有な薬
効を示すことが知られている。It is known that Chinese herbal medicines exhibit unique medicinal effects through various combinations.
しかし健胃生薬として分類されるものについては多数知
られているが、他の健胃生薬との組合わせによって調合
された漢方製剤の薬効について評価した例は認められて
いない。また健胃という概念の曖昧さもあって現代薬理
学的に有効性を示されたものは少ない。However, although there are many known herbal medicines classified as stomachic herbal medicines, there has been no evaluation of the medicinal efficacy of Chinese herbal preparations prepared in combination with other stomachic herbal medicines. Also, due to the ambiguity of the concept of ``healthy stomach'', there are few things that have been shown to be effective in modern pharmacology.
苦参、全姿、延胡索または甘草各法エキスまたは各チン
キはそれぞれ単味で健胃薬としての薬効が知られている
が、それらの組合わせによって単味以上の薬効が発現す
ることは知られていなかった。Extracts or tinctures of bitter ginseng, whole extract, licorice, and licorice are known to have medicinal effects as a stomachic medicine when used alone, but it is not known that a combination of these can have medicinal effects beyond that of the single flavor. There wasn't.
本発明者の抗潰瘍モデルを用いた薬理学的研究によれば
苦参流エキスもしくはチンキには強い抗潰瘍活性が認め
られ、延胡索流エキスもしくはチンキにも弱いながらも
抗潰瘍活性が認められたが、全姿及び甘草の各流エキス
もしくはチンキには抗潰瘍活性は認められなかった。し
かしながら驚くべきことに、苦参流エキスもしくはチン
キに対し上記のものを含む他の漢方流エキスもしくはチ
ンキを調合し、漢方製剤とすることにより苦参流エキス
もしくはチンキ単味での抗潰瘍活性以上の活性が得られ
ることが見い出された。すなわち、本発明は苦参流エキ
スもしくはチンキと、他の浅草流エキスもしくはチンキ
の１種以上、特に生要流エキスもしくはチンキ、延胡索
流エキスもしくはチンキ、及び甘草流エキスもしくはチ
ンキからなる群から選ばれる１種以上とを有効成分とし
て含有する抗潰瘍作用を有する医薬組成物に関する。According to a pharmacological study conducted by the present inventor using an anti-ulcer model, strong anti-ulcer activity was observed in Kokusan-ryu extract or tincture, and weak anti-ulcer activity was also observed in Enko-saku-ryu extract or tincture. However, no anti-ulcer activity was observed in whole licorice and licorice extracts or tinctures. Surprisingly, however, it was found that by blending other Chinese herbal extracts or tinctures, including the ones mentioned above, with Kusangen-ryu extract or tincture to create a Chinese herbal preparation, the anti-ulcer activity exceeded that of Kusanrin-ryu extract or tincture alone. It was found that the activity of That is, the present invention provides extracts or tinctures selected from the group consisting of Kurusan-ryu extract or tincture and one or more other Asakusa-ryu extracts or tinctures, particularly Seikan-ryu extract or tincture, Enkosaku-ryu extract or tincture, and Licorice-ryu extract or tincture. The present invention relates to a pharmaceutical composition having an antiulcer effect containing one or more of the following as an active ingredient.
上記組合わせ中苦参流エキスもしくはチンキと生姜流エ
キスもしくはチンキとの組合わせが抗潰瘍活性面で特に
効果的であり、これに上記他の浅草流エキスもしくはチ
ンキをさらに組合わせることにより一般に一層の効果を
期待できる。Among the above-mentioned combinations, the combination of Kusan-ryu extract or tincture and ginger-ryu extract or tincture is particularly effective in terms of anti-ulcer activity, and it is generally even more effective when combined with the other Asakusa-ryu extracts or tinctures mentioned above. You can expect the following effects.
上記各流エキスもしくはチンキとは苦参、全姿、延胡索
、甘草等の浅草から第１１改正日本薬局方「製剤総則」
に準じて製造した流エキス剤またはチンキ剤を意味する
。The above extracts or tinctures include bitter ginseng, whole ginseng, enkosaku, licorice, etc. From Asakusa, the 11th revised Japanese Pharmacopoeia "General Rules for Preparations"
means a liquid extract or tincture prepared in accordance with .
苦参流エキスもしくはチンキに対する上記他の浅草流エ
キスもしくはチンキの使用割合は組合わせによって異な
るが、通常前者ｌに対して後者合計で０．０５〜１．０
（ｗ／ｉｎ）が適当である。The ratio of the other Asakusa-ryu extracts or tinctures to the Kusan-ryu extract or tincture varies depending on the combination, but usually the total amount of the latter is 0.05 to 1.0 to 1 of the former.
(w/in) is appropriate.
苦参流エキスもしくはチンキと上記他の浅草流エキスも
しくはチンキとは上記のごとく組み合わせてそのまま経
口的使用に供してもよいが、１種以上の常用の医薬的に
許容される医薬補助剤と組み合わせた経口的医薬組成物
として使用してもよい。かかる経口医薬組成物の形態と
しては錠剤、粉末剤、顆粒剤、カプセル剤等の固体製剤
、溶液、懸濁液等の液状製剤が用いられる。経口投与用
固形剤は慣用の賦形剤（無水ケイ酸、台底ケイ酸アルミ
ニウム、乳糖、砂糖、コーンスターチ、微結晶セルロー
ス等）、結合剤（アラビアゴム、ゼラチン、ポリビニル
ピロリドン等）、滑剤（ステアリン酸マグネシウム、タ
ルク、シリカ等）、崩壊剤（馬鈴薯デンプン、カルボキ
シメチルセルロースカルシウム等）、湿潤剤（ポリエチ
レングリコール、ソルビタンモノオレエート、ラウリル
硫酸ナトリウム等）を含有することができる。錠剤は常
法に従ってコーティングしてもよい。経口用液状製剤は
水性もしくは油性の懸濁液、溶液、シロップ等にすれば
よく、または使用に先立って適当なビヒクルで再溶解し
得る乾、燥物であってもよい。The Kusan-Ryu extract or tincture and the other Asakusa-Ryu extract or tincture mentioned above may be combined as described above and subjected to oral use as is, but they may also be combined with one or more conventional pharmaceutically acceptable pharmaceutical adjuvants. It may also be used as an oral pharmaceutical composition. The forms of such oral pharmaceutical compositions include solid preparations such as tablets, powders, granules, and capsules, and liquid preparations such as solutions and suspensions. Solid preparations for oral administration contain conventional excipients (silicic anhydride, aluminum silicate, lactose, sugar, corn starch, microcrystalline cellulose, etc.), binders (gum arabic, gelatin, polyvinylpyrrolidone, etc.), and lubricants (stearin). (magnesium acid, talc, silica, etc.), disintegrants (potato starch, calcium carboxymethyl cellulose, etc.), and wetting agents (polyethylene glycol, sorbitan monooleate, sodium lauryl sulfate, etc.). Tablets may be coated according to conventional methods. Oral liquid preparations may be in the form of aqueous or oily suspensions, solutions, syrups, etc., or may be dry, dry products that can be redissolved in a suitable vehicle prior to use.
このような液状製剤は普通に用いられる乳化剤（レシチ
ン、ソルビタンモノオレエート等）、乳化助剤（ソルビ
ットシロップ、メチルセルロース、ゼラチン等）、非水
性ビヒクル（ココナツツ油、落花生油等）、酸化防止剤
、着色剤、香味料等を含有することができる。Such liquid preparations contain commonly used emulsifiers (lecithin, sorbitan monooleate, etc.), emulsifying aids (sorbitol syrup, methylcellulose, gelatin, etc.), non-aqueous vehicles (coconut oil, peanut oil, etc.), antioxidants, It may contain coloring agents, flavoring agents, etc.
本発明の医薬組成物は人間の消化性潰瘍の治療及び／ま
たは予防に有効である。本医薬組威物の投与量は潰瘍の
程度、患者の体質等の因子によって変動するが、一般的
には底入１日あたり各浅草流エキスもしくはチンキの合
計量として約１０ａ＋ｇ〜約５００ｍｇの範囲が適当で
ある。The pharmaceutical composition of the present invention is effective in treating and/or preventing peptic ulcers in humans. The dosage of this medicinal composition varies depending on factors such as the degree of ulcer and the patient's constitution, but generally the total amount of each Asakusa-ryu extract or tincture is in the range of about 10a+g to about 500mg per day. is appropriate.
つぎに本発明を実施した場合の抗消化性潰瘍作用と安全
性について実施例により説明する。さらに製剤例を示す
。Next, the anti-peptic ulcer effect and safety when the present invention is implemented will be explained using Examples. Furthermore, formulation examples are shown.
実施例１〜４ 抗消化性潰瘍作用（水浸拘束ストレス潰
瘍）
ｗｉｓｔａｒ系雄性ラット（体重約２５０ｇ）を２４時
間絶食後試験に用いた。水浸拘束ストレス（金網ゲージ
で拘束後、水温２２℃の水槽に浸す）を７時間負荷した
のちにラットを致死せしめ、胃を摘出してホルマリン処
置後前の粘膜に発生した水浸拘束ストレス誘致潰瘍の長
さ（旧）を測定した。Examples 1 to 4 Anti-peptic ulcer effect (water immersion restraint stress ulcer) Wistar male rats (body weight approximately 250 g) were used in the test after fasting for 24 hours. The rats were subjected to water immersion restraint stress (restrainted with a wire mesh gauge and then immersed in a water tank at a water temperature of 22°C) for 7 hours, then killed, and the stomachs were removed to induce water immersion restraint stress that had occurred on the mucosa before formalin treatment. The length of the ulcer (old) was measured.
−匹当たりの潰瘍の長さの合計を潰瘍係数とした。検体
は水浸拘束ストレス負荷の１時間前に経口投与した。コ
ントロール群と被験薬物投与群との潰瘍係数との差をコ
ントロール群の潰瘍係数で除して抑制率を算出した。
ッ下余白・ 八 ｍｋ
コントロール
比較例１５０００００６
２０５００００６
３００５０００６
４０００５００５
１ ４５０ ０ ５０ ０ ６２
４０５ ０ ４５ ５０ ６３
２８４ １５０ ３２ ３４ ６４ ４
０５ ５０ ４５ ０ ６２．０±０．３
０．８±０．２
１．６±０．２
３．０±０．０
２．８±０．２
０．５±０．２
０．５±０．５
０．４±０．３
０．７±０．４
６０．０
１９．０
５０．０
−２７．３
７５．０
７５．０
８０．０
６５．０
られなかった。- The sum of ulcer lengths per animal was taken as the ulcer coefficient. The specimen was orally administered 1 hour before water immersion restraint stress loading. The inhibition rate was calculated by dividing the difference in ulcer coefficient between the control group and the test drug administration group by the ulcer coefficient of the control group.
Lower margin/8 mk Control comparison example 15000006 20500006 30050006 40005005 1 450 0 50 0 62
405 0 45 50 63
284 150 32 34 64 4
05 50 45 0 62.0±0.3 0.8±0.2 1.6±0.2 3.0±0.0 2.8±0.2 0.5±0.2 0.5± 0.5 0.4±0.3 0.7±0.4 60.0 19.0 50.0 -27.3 75.0 75.0 80.0 65.0 Not possible.
（２） ａａ−ｙ系雄性マウス（体重２０〜２２ｇ）の
−群１０匹に苦参流エキス：延胡索流エキス：全姿流エ
キス：せ草流エキス＝ ３：３： ３ ：１（５０％エ
タノールエキス、重量）の割合に配合した漢方方剤を３
００Ｏｎ＋ｇ／ｋｇ経口投与し、１週間生死を観察した
が、死亡例は認められなかった。(2) To 10 male aa-y mice (body weight 20 to 22 g) in group 10 were given Kurusang Ryu extract: Enkosaku Ryu extract: Whole body Ryu extract: Segusa Ryu extract = 3:3:3:1 (50%) Herbal medicine mixed with ethanol extract, weight) at a ratio of 3
00On+g/kg was orally administered and life and death were observed for one week, but no deaths were observed.
製剤例１ 顆粒剤 常法により以下の組成を有する顆粒剤を製する。Formulation Example 1 Granule Granules having the following composition are prepared by a conventional method.
重量（信ｇ）
実施例５ 急性毒性試験
（１） ｄａ−ｙ系雄性マウス（体重２０〜２２ｇ）の
−群１０匹に苦参流エキス：全姿流エキス：せ草流エキ
ス＝４．５ ： ４．５ ：１ （５０％エタノールエ
キス、重量）の割合に配合した漢方方剤を３０００ｍｇ
／ｋｇ経口投与し、ｌａ間生死を観察したが、死亡例は
認めケイ酸アルミニウム
乳糖
デンプン
計
００
００
５０
００
製剤例２ 経口液状製剤
常法により以下の組成を有する経口液状製剤を製する。Weight (g) Example 5 Acute Toxicity Test (1) 10 DAY male mice (body weight 20-22 g) in the - group were given Kokusan-ryu extract: whole-body Ryu extract: Segusa-Ryu extract = 4.5 : 3000mg of Chinese herbal medicine blended at a ratio of 4.5:1 (50% ethanol extract, weight)
/kg was orally administered, and life and death were observed for a period of time, but no deaths were observed.Aluminum silicate lactose starch Total: 00 00 50 00 Formulation Example 2 Oral liquid preparation An oral liquid preparation having the following composition is prepared by a conventional method.
ニラコールｌＩＣ０−６０（可溶化剤） １２
０ｍｇチョウジチンキ（矯味剤） ０．０’
１ｍｌハツカ油（〃） ０．００２威
白糖 （甘味剤） ５．２ｍｇエ
タノール（溶解補助剤）０，４戚
安息香酸 （防腐剤） ２４ ｆｆ１
ｇバラオキシ安息香酸エチル（ｌＬｌｊ腐剤）
２ｍｇ〔発明の効果〕
苦参流エキスもしくはチンキまたはその固形分の抗消化
性潰瘍作用を１姿、延胡索及び甘草の各流エキスもしく
はチンキまたはその固形分の１種以上の併用により高め
ることができる。Niracol lIC0-60 (solubilizer) 12
0mg clove tincture (flavoring agent) 0.0'
1ml Peppermint oil (〃) 0.002 White sugar (sweetener) 5.2mg Ethanol (solubilizing agent) 0,4-benzoic acid (preservative) 24 ff1
g Ethyl oxybenzoate (lLlj preservative)
2mg [Effect of the invention] The anti-peptic ulcer effect of the bitter ginseng extract or tincture or its solid content can be enhanced by the combined use of one or more of the various extracts or tinctures or their solid content of 1. .
Claims (1)
スもしくはチンキの１種以上とを有効成分として含有す
る抗潰瘍作用を有する医薬組成物。 ２ その他の漢草流エキスもしくはチンキの１種以上が
生姜流エキスもしくはチンキ、延胡索流エキスもしくは
チンキ、及び甘草流エキスもしくはチンキからなる群か
ら選ばれる１種以上である請求項１記載の医薬組成物。[Scope of Claims] 1. A pharmaceutical composition having an anti-ulcer effect, which contains as active ingredients an extract or tincture of Kusarin and one or more other extracts or tinctures of herbal herbs. 2. The pharmaceutical composition according to claim 1, wherein one or more of the other herb extracts or tinctures is one or more selected from the group consisting of ginger extract or tincture, Enkoso extract or tincture, and licorice extract or tincture. thing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1201537A JPH0363229A (en) | 1989-08-02 | 1989-08-02 | Medicine composition having antitumor action |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1201537A JPH0363229A (en) | 1989-08-02 | 1989-08-02 | Medicine composition having antitumor action |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0363229A true JPH0363229A (en) | 1991-03-19 |
Family
ID=16442694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1201537A Pending JPH0363229A (en) | 1989-08-02 | 1989-08-02 | Medicine composition having antitumor action |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0363229A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423319A (en) * | 2011-11-08 | 2012-04-25 | 上海市浦东新区北蔡社区卫生服务中心 | Traditional Chinese medicine composition for treating oral ulcer |
| CN104784609A (en) * | 2015-04-22 | 2015-07-22 | 赵鸿鹏 | Gastrointestinal medicine |
-
1989
- 1989-08-02 JP JP1201537A patent/JPH0363229A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423319A (en) * | 2011-11-08 | 2012-04-25 | 上海市浦东新区北蔡社区卫生服务中心 | Traditional Chinese medicine composition for treating oral ulcer |
| CN104784609A (en) * | 2015-04-22 | 2015-07-22 | 赵鸿鹏 | Gastrointestinal medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100934955B1 (en) | Pharmaceutical composition and methods of using same | |
| US6811796B2 (en) | Preventive or therapeutic agent for pollen allergy, allergic rhinitis, atopic dermatitis, asthma or urticaria, or health food for prevention or improvement or reduction of symptoms thereof | |
| US20030185918A1 (en) | Nutritional supplements and methods of using same | |
| AU2002332464A1 (en) | Nutritional supplements and methods of using same | |
| HUE025117T2 (en) | Crude extracts from andrographis paniculata | |
| JPH03240735A (en) | Combination of compounds as anti- inflammatory agent isolated from turmeric spp | |
| JP2001513803A (en) | Plant extract composition, method for producing the same, and pharmaceutical composition containing the same | |
| DD238920A5 (en) | PROCESS FOR PREPARING AN IMPROVED DAMAGING DEFLECTIVE COMPOSITION | |
| JPH04169536A (en) | Therapeutic agent for osteoporosis | |
| JPH0363229A (en) | Medicine composition having antitumor action | |
| DK165966B (en) | IMPROVED PIROXICAM CONTAINING ANTI-INFLAMMATORY PREPARATION | |
| JP3452922B2 (en) | Plant-based medicament for increasing and regulating tone in smooth muscle organs | |
| KR102492496B1 (en) | Method for producing wild ginseng stomach protection pill using medicinal herbs having stomach protecting effect | |
| JPH01113317A (en) | Antiarrythmic agent | |
| JP2002510640A (en) | Herbal composition for prevention and treatment of AIDS | |
| Khan | EFFECT OF UNANI FORMULATIONS ON URETERIC CALCULUS (HISAT-E-HALIB)– | |
| US4732760A (en) | Curative and preventive agent for ulcers of digestive organs | |
| KR100208969B1 (en) | Anti-ulcers drug containing extract from chap-rice | |
| JP2681085B2 (en) | Gastritis treatment | |
| KR101931300B1 (en) | Composition for inhibiting oral inflammation comprising fractions Citrus Unshiu Peel | |
| JP2006206461A (en) | Composition for prevention/treatment of allergic disease | |
| EP1226827B1 (en) | Pharmaceutical composition comprising rutin and lespedeza capitata extract for treating oedema | |
| JP3851668B2 (en) | Pharmaceutical composition | |
| JP2003226650A (en) | Medicinal composition | |
| JP5233177B2 (en) | Oral composition containing Anchu powder and Shigyakusan extract |